Kimberly P Dunsmore, Stuart S Winter, Meenakshi Devidas, Brent L Wood, Natia Esiashvili, Zhiguo Chen, Nancy Eisenberg, Nikki Briegel, Robert J Hayashi, Julie M Gastier-Foster, Andrew J Carroll, Nyla A Heerema, Barbara L Asselin, Karen R Rabin, Patrick A Zweidler-Mckay, Elizabeth A Raetz, Mignon L Loh, Kirk R Schultz, Naomi J Winick, William L Carroll, Stephen P Hunger
PURPOSE: Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease. PATIENTS AND METHODS: From 2007 to 2014, Children's Oncology Group trial AALL0434 (ClinicalTrials.gov identifier: NCT00408005) enrolled 1,562 evaluable patients with T-ALL age 1-31 years who received the augmented Berlin-Frankfurt-Muenster (ABFM) regimen with a 2 × 2 pseudo-factorial randomization to receive escalating-dose methotrexate (MTX) without leucovorin rescue plus pegaspargase (C-MTX) or high-dose MTX (HDMTX) with leucovorin rescue...
October 1, 2020: Journal of Clinical Oncology